Press release: dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status confirmatory data to support us regulatory resubmission by year-end; if approved, dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years more than 300,000 people in the us suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines paris and tarrytown, ny, october 24, 2024. positive data from the phase 3 liberty-cupid study c evaluating the investigational use of dupixent (dupilumab) in biologic-naive patients with uncontrolled chronic spontaneous urticaria (csu) who receive background therapy with antihistamines will be presented in a late-breaking oral presentation at the american college of allergy, asthma and immunology (acaai) 2024 annual scientific meeting in boston, massachusetts.
REGN Ratings Summary
REGN Quant Ranking